Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excimer laser alternative for psoriasis:

This article was originally published in Clinica

Executive Summary

Laser Photonics subsidiary Acculase has applied for 510(k) marketing clearance in the US for its excimer laser to treat skin diseases such as psoriasis. It claims that the laser method will result in shorter treatment courses with fewer sessions than the currently used ultra-violet phototherapy, while avoiding exposure of the patient's whole body to ultraviolet light. Psoriasis affects 2% of the world's population and treatment costs are $5 billion in the US alone, said Carlsbad, California-based Laser Photonics.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel